Skip to main content
162 search results for:

Osteoporosis 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-11-2022 | Osteoporosis | News | Article
    approvalsWatch

    Abaloparatide recommended for EU approval to treat osteoporosis

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended approval of abaloparatide, a parathyroid hormone-related protein, for treating osteoporosis in postmenopausal women at increased risk for fracture.

  2. 26-05-2022 | Osteoporosis | News | Article
    News in brief

    UK recommendations support regular exercise for people with osteoporosis

    People with osteoporosis should do regular exercise to maximize bone health and reduce fall risk, says an expert consensus statement published in the British Journal of Sports Medicine .

  3. 02-05-2022 | Rheumatoid arthritis | Adis Journal Club | Article
    Rheumatology and Therapy

    Abnormalities of Peripheral Lymphocyte Subsets in Rheumatoid Arthritis Patients Complicated with Osteoporosis

    Authors: Ting Cheng, Sheng-Xiao Zhang, Jia Wang, Jun Qiao, Min-Jing Chang, Hong-Qing Niu, Guang-Ying Liu & Xiao-Feng Li Abstract Introduction Osteoporosis (OP) is one of the major comorbidities of rheumatoid arthritis (RA).

  4. 18-02-2022 | Osteoporosis | News | Article
    approvalsWatch

    EMA recommends approval of teriparatide biosimilar for osteoporosis

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of a teriparatide biosimilar for the treatment of osteoporosis.

  5. 24-11-2021 | Osteoporosis | News | Article

    Bisphosphonates ‘likely to be beneficial’ for most older women with osteoporosis

    Findings from a meta-analysis suggest that bisphosphonate therapy for osteoporosis is most likely to benefit postmenopausal women who have a life expectancy of more than 12 months.

  6. 28-04-2021 | BSR 2021 | Conference coverage | Article

    Suboptimal prescribing of osteoporosis medications in people with polymyalgia rheumatica

    Less than half of patients with polymyalgia rheumatica are prescribed medications for osteoporosis, despite clinical guidelines recommending bone protection for those on long-term glucocorticoid treatment, research suggests.

  7. 18-02-2019 | Osteoporosis | Editorial | Article

    Osteoporosis therapy: Drug holiday or not?

    Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

  8. 30-07-2020 | Osteoporosis | Highlight | Teaser
    medwireNews top story

    Delayed denosumab dosing could raise vertebral fracture risk in patients with osteoporosis

    Delaying denosumab injections by more than 16 weeks is associated with an increased risk for vertebral fracture among patients with osteoporosis, study findings indicate.

  9. 30-07-2020 | Osteoporosis | News | Article

    Delayed denosumab dosing could raise vertebral fracture risk in patients with osteoporosis

    Delaying denosumab injections by more than 16 weeks is associated with an increased risk for vertebral fracture among patients with osteoporosis, study findings indicate.

  10. 09-04-2020 | Osteoporosis | News | Article

    Meta-analysis supports efficacy of denosumab for glucocorticoid-induced osteoporosis

    Denosumab significantly increases bone mineral density in people with glucocorticoid-induced osteoporosis and may be more effective than bisphosphonates, show the results of a systematic review and meta-analysis.

  11. 07-11-2019 | Osteoporosis | News | Article

    Unfavorable risk–benefit profile of odanacatib for osteoporosis treatment

    The cathepsin K inhibitor odanacatib reduces the incidence of fracture in postmenopausal women with osteoporosis, but at the cost of an increased risk for cardiovascular events, indicate findings from the LOFT trial.

  12. 28-10-2019 | Osteoporosis | News | Article
    approvalsWatch

    EMA gives nod to romosozumab for severe postmenopausal osteoporosis

    medwireNews : The sclerostin inhibitor romosozumab has been recommended for approval in Europe, for the treatment of severe osteoporosis in postmenopausal women at high risk for fractures.

  13. 09-09-2019 | Osteoporosis | News | Article

    Denosumab plus high-dose teriparatide may improve postmenopausal osteoporosis

    Combining denosumab with high-dose rather than standard-dose teriparatide results in greater increases in spine and hip bone mineral density in postmenopausal women with osteoporosis, phase IV study data show.

  14. 27-08-2019 | Osteoporosis | Highlight | Teaser
    medwireNews top story

    Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

    Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

  15. 27-08-2019 | Osteoporosis | News | Article

    Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

    Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

  16. 18-02-2019 | Osteoporosis | Highlight | Teaser
    Expert opinion editorial

    Osteoporosis therapy: Drug holiday or not?

    Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

  17. 11-04-2019 | Osteoporosis | News | Article
    approvalsWatch

    FDA approves romosozumab for fracture prevention in osteoporosis

    medwireNews : The monoclonal antibody romosozumab has been approved in the USA for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

  18. 24-04-2019 | Osteoporosis | Highlight | Teaser
    medwireNews top story

    Long-term drug treatment may reduce fracture risk in women with osteoporosis

    Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

  19. 24-04-2019 | Osteoporosis | News | Article

    Long-term drug treatment may reduce fracture risk in women with osteoporosis

    Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

  20. 03-10-2018 | Osteoarthritis | News | Article
    News in brief

    Diabetes linked to elevated arthritis, osteoporosis risk

    Patients with diabetes have an increased risk for arthritis, osteoporosis, and musculoskeletal pain, study findings indicate.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.